**Performance of the new Illumigene® Mycoplasma LAMP assay for detection of *M. pneumonia***

L. Musger¹, V. Mattheeussen¹, K. Loens¹, H. Goossens¹  
¹Belgian Reference Centre for Respiratory Pathogens, University Hospital Antwerp, Belgium

### background

*Mycoplasma pneumoniae* is a common cause of respiratory tract infections. In Belgium, between 3,000 and 5,000 cases of *M. pneumoniae* infection were registered yearly between 2011 and 2016, mainly based on serology. However, due to suboptimal performance and high inter-test variability of serology assays, interest in better-performing molecular tests has increased lately. The aim of this study was to evaluate the performance of the new Illumigene® Mycoplasma Direct assay using a real-time PCR reference method. This Illumigene® assay is a loop-mediated isothermal amplification (LAMP) test requiring minimal hands-on time and delivering results within the hour.

### materials and methods

Dilution series (10⁻³-10⁻⁶) of five titrated *M. pneumoniae* reference strains (PI1428, JAP377, 3996PL, 4972BRA and 6303DES with stock concentration between 1,1x10⁷ and 6,5x10⁷ colour changing units/mL) were prepared. All dilutions were analysed using the Illumigene® Mycoplasma Direct assay (Meridian Bioscience), performed on the illumipro-10 LAMP amplification and detection system (Meridian Bioscience). The 2016 QCMD *M. pneumoniae* panel (n=10) and *M. pneumoniae*-positive respiratory specimens (n=14) were analysed in the same manner. The test performance was evaluated by comparing the results with those generated by an accredited in-house RT-PCR targeting the P1 gene.

### results

Sensitivity of the Illumigene® Mycoplasma Direct assay was 83.3%. Five out of six falsely negative samples were 10⁻⁵-10⁻⁶ dilutions of reference strains and one was a QCMD sample. For all of these, RT-PCR yielded only weakly positive reactions with Ct-values around the limit of detection. For reference strain 3996 PL, the Illumigene® assay was positive at the 10⁻⁶ dilution, whereas RT-PCR was negative. Importantly, full concordance was noted between the Illumigene® assay and RT-PCR using clinical samples.

### conclusion

The performance of the Illumigene® assay is comparable to that of our in-house RT-PCR, failing to detect only those samples with low bacterial load. In view of its limited hands-on time and short TAT, the Illumigene® assay can be used as a valid alternative for RT-PCR in settings with limited equipment or expertise in molecular diagnostics.

**correspondence:**  
Lorenz Musger  
lorenz.musger@uza.be  
University Hospital Antwerp  
Wilrijkstraat 10 - 2650 Edegem, Belgium

**acknowledgements/disclosures:**  
The National Reference Centre for Respiratory Pathogens is partially supported by the Belgian Ministry of Social Affairs through a fund within the Health Insurance System.

---

**strain / dilution** | **Illumigene®** | **RT-PCR / repeat RT-PCR**
--- | --- | ---
6303DES / 10⁻⁴ | negative | positive / positive (33,98)
4972BRA / 10⁻⁵ | negative | positive / positive (32,76)
JAP377 / 10⁻⁵ | negative | positive / positive (34,31)
JAP377 / 10⁻⁶ | negative | positive / not tested again
3996PL / 10⁻⁶ | positive | negative / negative (0,00)
PI1428 / 10⁻⁵ | negative | positive / positive (35,27)
QCMD 3 | negative | positive / positive (38,86)

**disCORDANT RESULTS**

**preparation steps for the Illumigene® Mycoplasma Direct Assay**